Percutaneous coronary intervention fibrinolytic-ineligible patients

Percutaneous Coronary Intervention Guidelines Microchapters
Home
Patient Information
Overview
PCI Approaches:
CAD Revascularization:
Heart Team Approach to Revascularization Decisions
Left Main Coronary Artery Disease
Intervention in left main coronary artery disease
Non-Left Main Coronary Artery Disease
Revascularization to Improve Symptoms
Dual Antiplatelet Therapy Compliance and Stent Thrombosis
Hybrid Coronary Revascularization
Pre-procedural Considerations:
Contrast-Induced Acute Kidney Injury
Anaphylactoid Reactions
Statin Treatment
Bleeding Risk
Role of Onsite Surgical Backup
Procedural Considerations:
Vascular Access
PCI in Specific Clinical Situations:
Asymptomatic Ischemia or CCS Class I or II Angina
CCS Class III Angina
Unstable Angina/Non–ST-Elevation Myocardial Infarction
ST-Elevation Myocardial Infarction:
General and Specific Considerations
Coronary Angiography Strategies in STEMI
Primary PCI of the Infarct Artery
Delayed or Elective PCI in patients with STEMI
Fibrinolytic-Ineligible Patients
Facilitated PCI
Rescue PCI
After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion
Cardiogenic Shock
Prior Coronary Bypass Surgery
Revascularization Before Non-cardiac Surgery
Adjunctive Diagnostic Devices:
Fractional Flow Reserve
Intravascular Ultrasound
Adjunctive Therapeutic Devices:
Coronary Atherectomy
Thrombectomy
Laser Angioplasty
Cutting Balloon Angioplasty
Embolic Protection Devices
Percutaneous Hemodynamic Support Devices
Antiplatelet therapy:
Oral Antiplatelet Therapy
Glycoprotein IIb/IIIa Receptor Antagonists
Intravenous Antiplatelet therapy:
STEMI
UA/NSTEMI
SIHD
Anticoagulant Therapy:
Parenteral Anticoagulants During PCI
Unfractionated Heparin
Enoxaparin
Bivalirudin and Argatroban
Fondaparinux
No-Reflow Pharmacological Therapies
PCI in Specific Anatomic Situations:
Chronic Total Occlusions
Saphenous Vein Grafts
Bifurcation Lesions
Aorto-Ostial Stenoses
Calcified Lesions
PCI in Specific Patient Populations:
Chronic Kidney Disease
Peri-procedural Myocardial Infarction Assessment
Vascular Closure Devices
Post-Procedural Considerations:
Post-procedural Antiplatelet Therapy
Proton Pump Inhibitors and Antiplatelet Therapy
Clopidogrel Genetic Testing
Platelet Function Testing
Restenosis
Exercise Testing
Cardiac Rehabilitation
Quality and Performance Considerations:
Quality and Performance
Certification and Maintenance of Certification
Operator and Institutional Competency and Volume
Percutaneous coronary intervention fibrinolytic-ineligible patients On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Percutaneous coronary intervention fibrinolytic-ineligible patients All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Percutaneous coronary intervention fibrinolytic-ineligible patients
CDC on Percutaneous coronary intervention fibrinolytic-ineligible patients
Percutaneous coronary intervention fibrinolytic-ineligible patients in the news
Blogs on Percutaneous coronary intervention fibrinolytic-ineligible patients
Directions to Hospitals Treating Percutaneous Coronary Intervention
Risk calculators and risk factors for Percutaneous coronary intervention fibrinolytic-ineligible patients

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

2005 ACC/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)

PCI in Fibrinolytic-Ineligible Patients (DO NOT EDIT)

Class I

"1.Primary PCI should be performed in fibrinolytic-ineligible patients who present with STEMI within 12 hours of symptom onset. (Level of Evidence: C) "

Class IIa

"1.It is reasonable to perform primary PCI for fibrinolytic- ineligible patients with onset of symptoms within the prior 12 to 24 hours and 1 or more of the following: a. Severe congestive heart failure. (Level of Evidence: C) b. Hemodynamic or electrical instability. (Level of Evidence: C) c. Evidence of persistent ischemia. (Level of Evidence: C)